Impact of continuous erythropoietin receptor activator on selected biomarkers of cardiovascular disease and left ventricle structure and function in chronic kidney disease

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Bartnicki, Piotr ^a   Rysz, Jacek ^a   Franczyk, Beata ^a   Baj, Zbigniew ^a   Majewska, Ewa ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; CARDIOLOGY; ECHOCARDIOGRAPHY; PATIENT TREATMENT;

ANTI-INFLAMMATORY ACTION; BIOCHEMICAL PARAMETERS; CARDIO-VASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; ENDOTHELIAL DYSFUNCTION; ERYTHROPOIETIN RECEPTORS; NEGATIVE CORRELATION;

DISEASES;

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CREATININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAS LIGAND; GELATINASE B; HEMOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; ERYTHROPOIETIN; MACROGOL DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; PROTEIN BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; DRUG EFFECTS; HEART VENTRICLE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC; VASCULAR ENDOTHELIUM;

AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; FEMALE; HEART VENTRICLES; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RENAL INSUFFICIENCY, CHRONIC; VENTRICULAR FUNCTION, LEFT;

EID: 84962263894     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/9879615     Document Type: Article

References (40)

1. G. A. Roth, M. D. Huffman, A. E. Moran, et al., "Global and regional patterns in cardiovascularmortality from1990 to 2013, " Circulation, vol. 132, no. 17, pp. 1667-1678, 2015.
2. Q. Y. Yao, R. Pecoits-Filho, B. Lindholm, and P. Stenvinkel, "Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease, " Scandinavian Journal of Urology and Nephrology, vol. 38, no. 5, pp. 405-416, 2004.
3. M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, et al., "Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention, " Hypertension, vol. 42, no. 5, pp. 1050-1065, 2003.
4. S. Wison, K. Foo, J. Cunninghamet al., "Renal function and risk stratification in acute coronary syndromes, "American Journal of Cardiology, vol. 91, no. 9, pp. 1051-1054, 2003.
5. C. A. Herzog, R. W. Asinger, A. K. Berger, et al., "Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO), " Kidney International, vol. 80, no. 6, pp. 572-586, 2011.
6. P. S. Tucker, A. T. Scanlan, and V. J. Dalbo, "Chronic kidney disease influences multiple systems: describing the relationship between oxidative stress, inflammation, kidney damage, and concomitant disease, " Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 806358, 8 pages, 2015.
7. M. Agharazii, R. St-Louis, A. Gautier-Bastien, et al., "Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcification, " American Journal of Hypertension, vol. 28, no. 6, pp. 746-755, 2015.
8. M. Pruijm, B. Ponte, P. Vollenweider, et al., "Not all inflammatory markers are linked to kidney function: results from a population-based study, " American Journal of Nephrology, vol. 35, no. 3, pp. 288-294, 2012.
9. Z. A. Massy, P. Stenvinkel, and T. B. Drueke, "The role of oxidative stress in chronic kidney disease, " Seminars in Dialysis, vol. 22, no. 4, pp. 405-408, 2009.
10. D. Fliser, "Asymmetric dimethylarginine (ADMA): the silent transition froman uraemic toxin to a global cardiovascular risk molecule, " European Journal of Clinical Investigation, vol. 35, no. 2, pp. 71-79, 2005.
11. V. Liakopoulos, T. Eleftheriadis, T. Kyropoulos, et al., "Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease, " Renal Failure, vol. 27, no. 3, pp. 315-321, 2005.
12. M. Sato, T. Konuma, N. Yanagisawa, H. Haizuka, H. Asakura, and Y. Nakashima, "Fas-Fas ligand system in the peripheral blood of patients with renal diseases, " Nephron, vol. 85, no. 2, pp. 107-113, 2000.
13. R. G. Fassett, S. K. Venuthurupalli, G. C. Gobe, J. S. Coombes, M. A. Cooper, and W. E. Hoy, "Biomarkers in chronic kidney disease: a review, " Kidney International, vol. 80, no. 8, pp. 806-821, 2011.
14. J. Rysz, M. Banach, R. A. Stolarek, et al., "Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy, " Journal of Nephrology, vol. 20, no. 4, pp. 444-452, 2007.
15. A. V. Fedulov, T. P. Ses, N. A. Gavrisheva, et al., "Serum TGFbeta1 and TNF-alpha levels and cardiac fibrosis in experimental chronic renal failure, " Immunological Investigations, vol. 34, no. 2, pp. 143-152, 2005.
16. L. M. Blanco-Colio, J. L. Martin-Ventura, E. de Teresa, et al., "Increased soluble Fas plasma levels in subjects at high cardiovascular risk: atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 168-174, 2007.
17. L. Del Vecchio and F. Locatelli, "Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies, " Expert Review of Hematology, vol. 7, no. 4, pp. 495-506, 2014.
18. P. K. Chatterjee, "Pleiotropic renal actions of erythropoietin, " The Lancet, vol. 365, no. 9474, pp. 1890-1892, 2005.
19. Y. Tanaka, N. Joki, H. Hase, et al., "Effect of erythropoietinstimulating agent on uremic inflammation, " Journal of Inflammation, vol. 9, no. 1, pp. 17-26, 2012.
20. P. Bartnicki, P. Fijalkowski, M. Majczyk, J. Blaszczyk, M. Banach, and J. Rysz, "Effect of methoxy polyethylene glycolepoetin beta on oxidative stress in predialysis patients with chronic kidney disease, " Medical Science Monitor, vol. 19, no. 8, pp. 954-959, 2013.
21. P. Bartnicki, E. Majewska, M. Kowalczyk, Z. Baj, M. Banach, and J. Rysz, "Impact of anemia treatment with methoxy polyethylene glycol-epoetin beta on polymorphonuclear cells apoptosis in predialysis patients with chronic kidney disease, " Pharmacological Reports, vol. 67, no. 5, pp. 842-845, 2015.
22. P. Pozzoni, M. Pozzi, L. Del Vecchio, and F. Locatelli, "Epidemiology and prevention of cardiovascular complication in chronic kidney disease patients, " Seminars in Nephrology, vol. 24, no. 5, pp. 417-422, 2004.
23. B. J. G. Pereira, L. Shapiro, A. J. King, M. E. Falagas, J. A. Strom, and C. A. Dinarello, "Plasma levels of IL-1, TNF and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients, " Kidney International, vol. 45, no. 3, pp. 890-896, 1994.
24. C. Garlanda, C. A. Dinarello, and A. Mantovani, "The interleukin-1 family: back to the future, " Immunity, vol. 39, no. 6, pp. 1003-1018, 2013.
25. T. Higuchi, N. Fukuda, C. Yamamoto, et al., "The influence of uremic serum on interleukin-1 and interleukin-1 receptor antagonist production by peripheral blood mononuclear cells, " Therapeutic Apheresis andDialysis, vol. 10, no. 1, pp. 65-71, 2006.
26. J. Gupta, N. Mitra, P. A. Kanetsky, et al., "Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC, " Clinical Journal of the American Society of Nephrology, vol. 7, no. 12, pp. 1938-1946, 2012.
27. B. T. Lee, F. A. Ahmed, L. L. Hamm, et al., "Association of Creactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease, " BMC Nephrology, vol. 16, article 77, 2015.
28. M. Bonomini, M. Reale, P. Santarelli, S. Stuard, N. Settefrati, and A. Albertazzi, "Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients, " Nephron, vol. 79, no. 4, pp. 399-407, 1998.
29. I. Kyriakos, V. S. Stel, E. Dounousi, et al., "Inflammation, endothelial dysfunction and increased left ventricular mass in chronic kidney disease (CKD) patients: a longitudinal study, " PLoS ONE, vol. 10, no. 9, Article IDe0138461, 2015.
30. H. Tabibi, A. Ashabi, M. Mahdavi-Mazdeh, M. Hedayati, and B. Nozary-Heshmati, "Comparison of novel risk factors for cardiovascular disease between hemodialysis patients with and without protein-energy wasting, " International Urology and Nephrology, vol. 46, no. 10, pp. 2015-2020, 2014.
31. J. Rysz, M. Banach, R. A. Stolarek, et al., "Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis, " International Urology and Nephrology, vol. 43, no. 2, pp. 491-498, 2011.
32. J. Rysz, E. Majewska, R. A. Stolarek, M. Banach, A. Cialkowska-Rysz, and Z. Baj, "Increased levels of soluble TNF-receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis, " American Journal of Nephrology, vol. 26, no. 5, pp. 437-444, 2006.
33. J. L. Martin-Ventura, L. M. Blanco-Colio, B. Munoz-Garcia, et al., "NF-B activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability, " Stroke, vol. 35, no. 2, pp. 458-463, 2004.
34. M. Nairz, T. Sonnweber, A. Schroll, I. Theurl, and G. Weiss, "The pleiotropic effects of erythropoietin in infection and inflammation, " Microbes and Infection, vol. 14, no. 3, pp. 238-246, 2012.
35. D. S. Silverberg, D. Wexler, A. Iaina, and D. Schwartz, "The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions, " Clinical and Experimental Nephrology, vol. 13, no. 2, pp. 101-106, 2009.
36. J.-Y. Choi, C. W. Yang, Y.-H. Kim, et al., "Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients, " Kidney and Blood Pressure Research, vol. 37, no. 4-5, pp. 259-268, 2013.
37. J. K. Inrig, S. K. Bryskin, U. D. Patel, M. Arcasoy, and L. A. Szczech, "Association between high-dose erythropoiesisstimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors, "BMCNephrology, vol. 12, no. 1, pp. 67-77, 2011.
38. G. Bellinghieri, C. G. Condemi, S. Saitta, et al., "Erythropoiesisstimulating agents: dose and mortality risk, " Journal of Renal Nutrition, vol. 25, no. 2, pp. 164-168, 2015.
39. M. P. Curran and P. L. McCormack, "Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease, " Drugs, vol. 68, no. 8, pp. 1139-1156, 2008.
40. N. Shushakova, J. K. Park, J. Menne, and D. Fliser, "Chronic erythropoietin treatment affects different molecular pathways of diabetic cardiomyopathy in mouse, " European Journal of Clinical Investigation, vol. 39, no. 9, pp. 755-760, 2009.